Pharmaceutical r&d performance by firm size: Approval success rates and economic returns

American Journal of Therapeutics

Volumn 21, Issue 1, 2014, Pages 26-34

  Dimasi, Joseph A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

approval success rates; firm size; pharmaceutical R D

Indexed keywords

BIOTECHNOLOGY; DATABASES, FACTUAL; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; LEGISLATION, DRUG; RESEARCH;

EID: 84894062929     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318269198f     Document Type: Article

References (21)

1. Paul SM, Mytelka DS, Dunwiddie T, et al. How to improve R&D productivity: The pharmaceutical industry?s grand challenge. Nat Rev Drug Discov. 2010;9: 203-214.
2. Munos BH. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959-968.
3. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther. 2011;89:183-188.
4. DiMasi JA, Hansen RW, Grabowski HG, et al. Cost of innovation in the pharmaceutical industry. J Health Econ. 1991;10:107-142.
5. Office of Technology Assessment, U.S. Congress. Pharmaceutical R&D: Costs, Risks, and Rewards. Washington, DC: GPO; 1993.
6. DiMasi JA, Hansen RW, Grabowski HG, et al. Research and development costs for new drugs by therapeutic category: A study of the U.S. pharmaceutical industry. Pharmacoeconomics. 1995;7:152-169.
7. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ. 2003;22:151-185.
8. DiMasi JA, Grabowski HG, Vernon J. R&D costs and returns by therapeutic category. Drug Inf J. 2004;38: 211-223.
9. DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: Is biotech different Manag Decis Econ. 2007;28: 285-291.
10. Adams PA, Brantner VV. Spending on new drug development. Health Econ. 12010;9:130-141.
11. DiMasi JA, Feldman L, Seckler A, et al. Trends in risks associated with new drug development: Success rates for investigational drugs. Clin Pharmacol Ther. 2010;87: 272-277.
12. Sams-Dodd F. Target-based drug discovery: Is something wrong Drug Discov Today. 2005;10:139-147.
13. Swinney DC, Anthony J. How were new medicines discovered Nat Rev Drug Discov. 2011;10:507-519.
14. Scannell JW, Blanckley A, Bolden H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191-200.
15. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther. 1995;58: 1-14.
16. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther. 2001; 698:297-307.
17. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates Nat Rev Drug Discov. 2004;3:711-715.
18. Shulman SR, Bienz-Tadmor B, Seo PS, et al. Implementation of the orphan drug act: 1983-1991. Food Drug Law J. 1992;47:363-403.
19. DiMasi JA, Grabowski HG, Vernon J. R&D costs, innovative output, and firm size in the pharmaceutical industry. Int J Econ Bus. 1995;2:201-219.
20. Grabowski HG, Kyle M. Mergers, acquisitions, and alliances. In: Danzon PM, Nicholson S, eds. The Oxford Handbook of the Economics of the Biopharmaceutical Industry. Oxford, United Kingdom: Oxford University Press; 2012:552-577.
21. Danzon PM, Nicholson S, Pereia NS. Productivity in pharmaceutical- biotechnology R&D: The role of experience and alliances. J Health Econ. 2005;24:317-339.